SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.

Blog

jubilant

Jubilant Life stock rises after Q4FY18 PAT gains

The company’s consolidated revenue in Q4FY18 rose 40.9% to Rs2,252cr vs Rs1,598cr in Q4FY17.

Jubilant Life Sciences Ltd is currently trading at Rs857.05 up by Rs10.3 or 1.22% from its previous closing of Rs846.75 on the BSE. PAT grew by 2.3% yoy to Rs152.4cr. The PAT came lower as company had booked one‐time charges, adjusted for which PAT growth is higher at 63.3% yoy to Rs243cr in Q4FY18.

The company’s consolidated revenue in Q4FY18 rose 40.9% to Rs2,252cr vs 1,598cr in Q4FY17.

EBITDA in Q4FY18 was up 50.1% yoy to Rs458cr vs Rs305cr in Q4FY17.EBITDA margins were at 20.3% in Q4FY18 vs. 20.2% in Q3FY18 and 19.1% in Q4FY17.

The pharmaceutical segment sales grew by 54% yoy to Rs1,238cr, while Life Sciences Ingredient (LSI) segment sales grew by 43% yoy to 968cr in Q4FY18.

The scrip opened at Rs862 and has touched a high and low of Rs880 and Rs851.50 respectively.